Last reviewed · How we verify
emtricitabine, tenofovir, ritonavir, atazanavir
emtricitabine, tenofovir, ritonavir, atazanavir is a Small molecule drug developed by International Medical Center of Japan. It is currently FDA-approved.
Emtricitabine, tenofovir, ritonavir, and atazanavir, marketed by the International Medical Center of Japan, is a combination therapy currently available in the market. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of disclosed revenue data, which may affect investment and market valuation.
At a glance
| Generic name | emtricitabine, tenofovir, ritonavir, atazanavir |
|---|---|
| Sponsor | International Medical Center of Japan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (PHASE4)
- Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia (NA)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- emtricitabine, tenofovir, ritonavir, atazanavir CI brief — competitive landscape report
- emtricitabine, tenofovir, ritonavir, atazanavir updates RSS · CI watch RSS
- International Medical Center of Japan portfolio CI